The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Name on ClinicalTrials.gov (link is external) |
Quality of Life in Cystic Fibrosis Patients Treated With Lumacaftor/Ivacaftor (Orkambi) or Tezacaftor/Ivacaftor (Symkevi) and Primary Caregivers in the United Kingdom |
|---|---|
| Study Drug | none/real world evidence trial |
| Type of Study Drug | - |
| Study Title | Quality of Life in Cystic Fibrosis Patients Treated With Lumacaftor/Ivacaftor (Orkambi) or Tezacaftor/Ivacaftor (Symkevi) and Primary Caregivers in the United Kingdom |
| Study Phase | IV |
| Study Sponsor | Vertex |
| Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
| Age | Adult and pediatric patients, adult caregivers |